MNKKQ Stock Recent News

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange (NYSE), the two drugmakers said Thursday.

Drugmakers Mallinckrodt Pharmaceuticals and Endo Inc announced they have entered into a merger agreement to create a larger, diversified pharmaceuticals company valued at about $6.7 billion. Both Mallinckrodt and Endo have faced significant financial challenges in recent years driven by opioid-related lawsuits, leading to multiple bankruptcy filings.

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint.

The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in 2025 and at least $150 million of annual operating synergies by year three.

Transaction Brings Together Two Highly Complementary Businesses to Broaden Patient Access and Develop New Therapies to Address Unmet Patient Needs Combined Company Expected to Benefit from Immediate Scale, Robust Cash Flow and Enhanced Financial Flexibility to Invest in Internal and External Growth Opportunities; Net Leverage of Approximately 2.3x Expected at Close Strategic Combination Expected to Generate at Least $150 Million of Annual Operating Synergies by Year 3 and Approximately $75 Million in Year 1 Combined Company Is Expected to Be Listed on the New York Stock Exchange (NYSE) Companies Plan to Operationally Combine Respective Generics Businesses and Endo's Sterile Injectables Business Following Close of Transaction; Intend to Separate That Combined Business at a Later Date Heavily U.S.-Focused Footprint with Proven Strong Track Records of High Quality and Reliability Companies to Host Joint Conference Call and Webcast Today at 8:00 a.m. ET DUBLIN and MALVERN, Pa.

Mallinckrodt Pharmaceuticals and Endo are exploring a potential merger that could be valued at about $7 billion, Bloomberg News reported on Wednesday, citing people with knowledge of the matter.

DUBLIN , March 10, 2025 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today announced that it has rescheduled the release of its fourth quarter and fiscal year 2024 financial results and earnings conference call. The Company will now report earnings before market open on Thursday, March 13, 2025.

DUBLIN , Feb. 27, 2025 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today announced that it will report its fourth quarter and fiscal year 2024 financial results on Tuesday, March 11, 2025.  A conference call for investors will begin at 8:00 a.m.

SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Mallinckrodt Securities Litigation: UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY BARBARA STROUGO, Individually and on Behalf of All Others Similarly Situated,   No. 3:20-cv-10100-RK (TJB)         Plaintiff, CLASS ACTION     vs. SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION       MALLINCKRODT PUBLIC LIMITED COMPANY, et al.,       Defendants.     TO.

–  The INOmax EVOLVE DS is our next-generation nitric oxide delivery system that combines mini-cylinder technology, automation, integration, and interaction into one device1 – – The INOmax EVOLVE DS is now available for contracting and distribution for use in U.S. hospitals – DUBLIN , Oct. 10, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the rollout of the U.S. Food and Drug Administration (FDA) cleared INOmax® EVOLVE™ DS delivery system for the delivery of INOmax® (nitric oxide) gas, for inhalation. This nationwide rollout follows the successful introduction of the INOmax EVOLVE DS Pilot program.